The type 2 diabetes drug rosiglatazone could increase patients' risk of bone fractures and osteoporosis, research shows.
A study published in Nature Medicine says rosiglitazone prevents osteoblast cells from building bone and is associated with an increased risk of fracture.
Director of Research at Diabetes UK Iain Frame said: "We already know that bone fractures are more common in people with diabetes taking rosiglitazones. This research could help us to understand better the effect the drug may have on bone heath.
"However, a lot more research is needed before we can conclusively link rosiglitazones to increased risk of various bone conditions in humans."
Both the Medicines and Healthcare products Regulatory Agency and the European Medicines Agency have not altered their recommendation for patients with diabetes to take glitazones.